Related Experiment Video
Updated: Sep 26, 2026

Expired CO2 Measurement in Intubated or Spontaneously Breathing Patients from the Emergency Department
Published on: January 29, 2011
Smoking cessation in emergency departments: a reality check
D Campagna1,2,3, F Cucuzza4,5, C Russo6
1Center of Excellence for Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy. davide.campagna@unict.it.
Abstract:
Emergency Departments (EDs) see a high prevalence of people who smoke, many of whom present with acute smoking-related conditions (e.g., myocardial infarction, stroke, pneumonia, and asthma/COPD exacerbations). The immediacy of illness creates a strong "teachable moment," increasing receptiveness to risk communication and behavior change. Evidence indicates that pairing brief counseling with point-of-care therapeutic support and structured follow-up improves abstinence, although effects vary with local infrastructure, product availability, and staffing models. Despite this promise, scale-up is often constrained by economic barriers, limited staffing and training, and weak integration of cessation workflows into routine ED practice. The aim of this article is to provide a reality check on ED-based smoking cessation by synthesizing evidence on effectiveness, feasibility, cost-effectiveness, and safety across health-system contexts, and by outlining pragmatic delivery models and research priorities. Embedding low-friction, clinically governed cessation bundles within EDs has the potential to convert acute presentations into durable quit attempts and reduce smoking-related harm at scale, though this population-level impact remains a hypothesis to be tested. Future work should prioritize pragmatic and implementation trials with biochemically verified outcomes, integration metrics, equity impacts, and cost-utility analyses to guide sustainable adoption across diverse settings.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
PPE Use in Healthcare Settings II: Doffing
CNS Depressants: Alcohol and Nicotine
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
COPD: Management Using Bronchodilators and Corticosteroids
